Lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 5 SUPPL.1, 2007, Pages

  Crinò, Lucio ^a   Foglietta, Jennifer ^a   Hamzaj, Alketa ^a  

^a Perugia Hospita ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APRINOCARSEN; BEVACIZUMAB; BEXAROTENE; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IONAFARNIB; IRINOTECAN; NAVELBINE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PACLITAXEL; PEMETREXED; PF 3512676; PLACEBO; SORAFENIB; UNCLASSIFIED DRUG; VANDETANIB; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; VASCULOTROPIN RECEPTOR;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; DRUG ANTAGONISM; LUNG TUMOR; MEDICAL RESEARCH; PHARMACOGENETICS; REVIEW;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CARCINOMA, NON-SMALL-CELL LUNG; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 34250367527     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000268637.10332.e3     Document Type: Conference Paper

References (30)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. Haus BM, Ravazi H, Kuschner WG. Occupational and environmental causes of bronchogenic carcinoma. Curr Opin Pulm Med 2001;7: 220-225.
3. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S-49S.
4. Jemal A, Murray T, Wand E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
5. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta analysis using data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
6. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;4:1087-1100.
7. Jaakkimainen L, Goodwin PJ, Pater J, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small-cell lung cancer. J Clin Oncol 1990; 8:1301-1309.
8. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
9. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-1561.
10. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
11. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13:737-741.
12. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194.
13. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 2000;11:435-440.
14. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001;92:595-600.
15. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small-cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005;11:690-696.
16. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003;22:3548-3553.
17. Bepler G. Pharmacocogenomics: a reality or still a promise? Lung Cancer 2006;54:3S-7S.
18. Rosell R, Cobo M, Isla D, et al. ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p) (Abstract). J Clin Oncol 2005;23:7002.
19. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
20. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
21. Yuan JA, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001;19:432-441.
22. Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997;74:64-68.
23. Johnson D, Fehrebacher L, Novotny WZ, Herbst R. Randomized phase II trial comparing bevacizumab plus carboplatino and paclitaxel with carboplatino and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
24. Laskin JJ, Sandler AB. First-line treatment for advanced non-small-cell lung cancer. Oncology 2005;19:1671-1676.
25. Herbst RS, Johnson BE, Rowbottom JA, et al. ZD6474 plus docetaxel in patients with previously treated NSCLC: results of a randomized, placebo-controlled Phase II trial (Abstract). Lung Cancer 2005;49:S35.
26. Blumenschein GR, Khuri F, Gatzemeier U, et al. A randomised Phase II trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/ paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer (NSCLC) (Abstract). J Clin Oncol 2005;23:7001.
27. Jassem J, Zatloukal P Ramlau R, et al. A randomized Phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy-naive patinets with advanced or metastatic non-small-cell lung cancer (NSCLC) (Abstract). J Clin Oncol 2005;23:7024.
28. Blumenschein G, Ludwig C, Thomas G, et al. A randomized phase III trial of Ionafarnib /carboplatin/paclitaxel vs CP in chemotherapy naive patients with stage IIIB and IV NSCLC (Abstract). Lung Cancer 2005;49:S30.
29. Lynch TJ, Raju R, Lind M, et al. Randomised Phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report (Abstract). Proc Am Soc Clin Oncol 2003;22:623.
30. Paz-Ares L, Douillard J, Koralewski P, et al. Randomized Phase III tria of gemcitabine/cisplatin (GC) and protein kinase C (PKCa antisense oligonucleotide aprinocarsen in patients (pts) with advancesstage non-small-cell lung cancer (NSCLC) (Abstract). J Clin Oncol 2005;32:7053.